CTLA4 and melanoma: It should be noted that pathway inhibitors have shown a potential synergistic effect with other antitumor agents in melanoma such as checkpoint inhibitors (56) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies (57).